Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Spectrum of MECP2 mutations in Vietnamese patients with RETT syndrome

BMC Medical Genetics201819:137

https://doi.org/10.1186/s12881-018-0658-x

  • Received: 20 March 2018
  • Accepted: 30 July 2018
  • Published:
Open Peer Review reports

Abstract

Background

Rett syndrome (RTT) is a severe neurodevelopmental disorder in children characterized by a normal neurodevelopmental process in the first 6–18 months followed by a period of motor and vocal deterioration with stereotypic hand movements. Incidence of RTT is mostly due to de novo mutation in the MECP2 gene (methyl-CpG-binding protein 2).

Methods

The study assessed 27 female patients presented with classical RTT phenotype age range from 18 months to 48 months. Specialist carried out the clinical evaluation and diagnosis according to RTT diagnosis criteria. Blood samples from patients were then collected for genomic DNA extraction. We next performed MECP2 gene amplification and sequencing of the whole coding region to screen for mutations.

Result

MECP2 mutation was found in 20 patients (74%) including: 2 missense, 4 nonsense, 6 frameshift and 2 deletion mutation. The study identified 14 pathogenic mutations which we found 4 mutation, to our knowledge and extensive search, not priory reported in any mutation database or publication: c.1384-1385DelGT, c.1205insT, c.717delC and c.1132_1207del77. High percentage of C > T (70%) in CpG sites mutation was found.

Conclusion

Our result reveals a high percentage of C > T mutation in CpG hot spot, which is more prone to modification and more likely to be detected in RTT as a disorder is strictly due to de novo mutations. The study is the first to identify the mutation spectrum of MECP2 gene in Vietnamese patients and also an important step toward better diagnosis and care for RTT patients in Vietnam.

Keywords

  • RETT syndrome
  • Neurodevelopmental disorder
  • MECP2
  • Mutation spectrum
  • de novo
  • Novel mutation

Background

Rett syndrome (RTT; OMIM Entry #312750) is a neurodevelopmental disorder which is one of the main causes of neurological disability in children [1]. Rett syndrome almost occurs in females, the estimate incident of RTT worldwide is 1:10.000–1:15000 female births [2]. The classic clinical presentation of RTT is characterized by average psychomotor progression from birth until 6–18 months, and then development halted followed by period of psychomotor deterioration [3, 4] . During the phase of deterioration, the patients often present stereotypic movements (classic RTT hand), loss of acquired motor skills and communication skills [5]. The neurodevelopmental of the child may stabilize or in some case, limited recovery can be observed in the next phase called the pseudo-stationary stage [6]. Other complications and symptoms of RTT may include seizure, cardiac abnormalities, irregular breathing patterns and scoliosis [79]. The level of motor impairment becomes more severe as the child’s age [10]. There are also atypical RTT patients whom present with several but not all clinical features and progression phases of classical RTT [11].

The most common cause of RTT is de novo mutations in the MECP2 gene (Methyl-CpG binding protein 2), located on the X chromosome (locus Xq28) [1]. Additionally, the gene is also subjected to X-chromosome inactivation, which alters the severity and manifestation of RTT [12]. The MECP2 gene consists of four exons and encode for the widely expressed methyl-CpG-binding protein 2 – member of the methyl-binding domain protein family. MECP2 is an important transcription factor, which functions by interaction and modification of epigenetic factors [13]. There exist two isoforms of MECP2 (MeCP2_e1 and MeCP2_e2) which have slight difference in their expression levels between tissues and distinct N termini. MeCP2_e1 is most commonly found in the brain tissue whilst MeCP2_e2 predominate in the placenta, liver and skeletal muscle tissues [14, 15]. Many studies have addressed MECP2 role in RTT, beside the critical role in neurodevelopmental process, MECP2 have been hypothesized to help maintenance of synaptic function, brain cell connectivity and neuronal plasticity [16, 17].

To date, around 1000 disease-causing MECP2 mutations have been characterized and recorded in multiple databases such as RettBASE and The Human Gene Mutation Database [18]. Case reports of asymptomatic carriers or carriers with mild clinical symptoms have been found to have skewed X chromosome inactivation (XCI) in preference of the normal copy of MECP2 [12]. In addition, MECP2 mutations have been loosely associated with other pediatric neurological conditions, most notably autism, Angelman syndrome, and many behavioral and intellectual disorders [19, 20].

In Vietnam, the lack of awareness and knowledge is also a major problem as consultation measures need to be provided families of RTT patients. Diagnosis of RTT require both clinical and molecular evidence, in which characterization of MECP2 gene is required for the disorder and provide valuable information for clinician in planning care and treatments.

In this study we first report the mutation spectrum of MECP2 in Vietnamese patients with clinically diagnosed for Rett syndrome, in which 4 novel mutations was found. This finding is an important step toward understanding and development of therapy to help patients suffering from RTT.

Methods

Study population

The study assessed 27 female patients presented with sporadic, RTT phenotype; diagnosis were made based on the criteria by Neul et al. [11]. Specialized pediatricians and neurologists at Vinmec hospital made clinical evaluation and confirmation of RTT. The Ethical board of Vinmec International Hospital approved of the study; informed consent was obtained from the parents of the patients.

Inclusion criteria

Female patients were recruited in the study based on classic presentation of RETT syndrome: average psychomotor progression from birth until 6–18 months of age, with no history of brain injury, trauma or serious infection. The patients presented with 2 out of 4 main clinical criteria:
  • Loss of acquired hand skills

  • Loss of acquired language skill

  • Gait abnormalities: impaired (dyspraxic) or absence of ability

  • Stereotypic hand movements

Molecular analysis

The genomic DNA was extracted from patient’s peripheral blood using the Wizard® Genomic DNA Purification Kit (Promega). The DNA quality was tested by the NanoDrop spectrophotometer. In order to perform mutant analysis, we designed primers to amplify the complete coding region (exon 2, 3, 4) including flanking intronic splice site sequence and 5’UTR within exon 2 and 3’UTR based on published genomic sequence of MECP2.

DNA was amplified by manual PCR method using GoTaq® Green Master Mix (Promega) on the GeneAmp PCR system 9700 thermocycler. The PCR product was checked on agarose gel and purified using QIAquick PCR purification Kit (Qiagen) according to the manufacturer’s instruction. The purified PCR product was sequenced directly in both strands using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) by automated fluorescent sequencing technology (Applied Biosystems 3500 Dx Genetic Analyzer). We used DNAstar to compare the patients’ MECP2 sequences with the reference MECP2 sequence (Genebank accession number. MECP2 locus, AF030876; MECP2, ENSG00000169057). The novel mutation was confirmed by doing extensive search on RettBASE and The Human Gene Mutation Database as well as from prior publications. We used in silico analysis to predict the consequence of the mutation identified in our cohort. The tool used were Polyphen-2 [21] and MutationTaster [22].

Results

Mutation analysis of the MECP2 gene

Mutation analysis was conducted in 27 female patients. The diagnosis followed the standard protocol: After clinical evaluation, blood sample was taken and PCR with the designated primers (Table 1) was used to amplify MECP2, followed by Sanger sequencing of the exons and compare with reference sequence to detect mutations. On clinical examination, all patients presented with history of a period of neurodevelopmental regression followed by recovery or stabilization, together with partial or complete loss of motor and language skill and stereotypic hand movements.

Mutation analysis detected MECP2 mutation in 20 out of 27 patients (mutation detection rate 74%)(Table 2). The study identified 14 pathogenic mutations, including 2 missenses, 4 nonsenses, 6 frame shifts and 2 deletions. The mutations that occur more frequently were c.473 C > T (n = 4); c.808 C > T (n = 4), c.763 C > T (n = 2) and c.502C > T (n = 2). All mutation were predicted to be disease causing by in silico analysis (Table 3).
Table 1

Primers used in MECP2 amplification

Amplicon

Length (bp)

Forward primer

Reverse primer

Exon 2

355

TAGCCCTGGGAAAAAGGTCG

GGCACAGTTTGGCACAGTTAT

Exon 3

484

CCTGCCTCTGCTCACTTGTT

CATGAGGGATCCTTGTCCCTG

Exon 4.1

429

TGCCCTATCTCTGACATTGCT

ATGACCTGGGTGGATGTGGT

Exon 4.2

631

GTCCTGGGAAGCTCCTTGTC

CTCTCCAGTGAGCCTCCTCT

Exon 4.3

388

CAGCGTCTGCAAAGAGGAGA

CCCTGAAGCCACGAAACTCT

Table 2

Mutation alleles frequency of RETT patients

Patient No.

Mutation of MECP2

Mutation type

Novel mutation

Nucleotide change

Amino acid change

1–4

c.473C > T

p.T158 M

Missense

No

5–8

c.808C > T

p. R270X

Nonsense

No

9–10

c.763C > T

p.R255X

Nonsense

No

11–12

c.502C > T,

p. R168X

Nonsense

No

13

c.1384-1385del GT

V462fs

Frameshift

Yes

14

c.763C > T

p.R255X

Nonsense

No

 

c.1205insT

p.P402Lfs

Frameshift

Yes

15

Exon 4 deletion

_

Large deletion

No

16

c.(164–182)del 19

p.Q56fs

Frameshift

No

 

(1148–1193)del 46

p.L383fs

Frameshift

No

17

c.717del C

p.A240fs

Frameshift

Yes

18

c.806del G

p. G269fs

Frameshift

No

19

c.1132_1207del77

A378fs

Deletion

Yes

20

c.917G > A

p.R306H

Missense

No

Table 3

In silico analysis to determine the causal relationship of the mutation and RETT syndrome

Nucleotide change

Amino acid change

Domain

MutationTaster

PolyPhen-2

Reference

c.473C > T

p.T158 M

MDB

Disease causing

Probably damaging with a score of 1.000

Rettbase

c.808C > T

p. R270X

TRD-NLS

Disease causing

N/A

Rettbase

c.763C > T

p.R255X

TRD

Disease causing

N/A

Rettbase

c.502C > T,

p. R168X

Inter-domain region

Disease causing

N/A

Rettbase

c.1384-1385del GT

p.V462fs

C- term

Disease causing

N/A

Novel

c.763C > T

p.R255X

TRD

Disease causing

N/A

Rettbase

c.1205insT

p.402Lfs

C - term

Disease causing

N/A

Novel

c.(164–182)del 19

p.Q56fs

TRD-NLS, 3’UTR

Disease causing

N/A

Rettbase

c.(1148–1193)del 46

p.L383fs

C - term

Disease causing

N/A

Rettbase

c.717delC

p.A240fs

TRD

Disease causing

N/A

Novel

c.806delG

p. G269fs

TRD-NLS

Disease causing

N/A

Rettbase

c.1132_1207del77

A378fs

C – term

Disease causing

N/A

Novel

c.917G > A

p.R306H

TRD

Disease causing

Probably damaging with a score of 0.999

Rettbase

N/A: Not applicable

A novel mutation was also identified: c.1384–1385 del GT (Fig. 1), a two-nucleotide deletion which lead to frameshift and alter the amino-acid sequence and premature termination of the protein product. The carrier was a female patient diagnosed with classic RTT at the age of 3. We also identified 3 other novel mutations: c.1205insT, c.717delC and c.1132_1207del77, to the best of our knowledge, not described in the MECP2 mutation database (Rettbase) or previously described in any publication.
Fig. 1
Fig. 1

Sanger sequencing result of the patient with novel mutation (c.1384–1385 del GT)

In silico prediction of mutation

Two in silico tool (Polyphen-2, MutationTaster) were used to predict the consequence of mutation. We identified the region change, probability of disease causing and potential changes to protein structure of each mutation identified in our cohort.

Discussion

The current study investigated the mutation spectrum of MECP2 in Vietnamese patients. The patients had been enrolled and pediatricians and neurologists carried out clinical evaluation. Therefore, the cohort is well defined and well suited for molecular study. Prior to availability of MECP2 mutation test, criteria for Rett syndrome diagnosis are based on a collection of clinical features organized into age-related stages [23]. Classic Rett syndrome was classified for girls meeting all main criteria while variants of this disorder were marked for patients with a less severe clinical presentation, including preserved speech or hand use, normal head circumference, or delayed symptom onset.

Mutations of MECP2 gene are highly correlated with RTT and have been found in other neurological disorder such as autism, Angelman syndrome, and other behavioral and intellectual disorders. Therefor molecular diagnosis for MECP2 mutations is an important step in diagnosis of neurodevelopmental disorders. Routine diagnostic protocol for MECP2 mutations is often carried out by DNA sequencing because of the gene’s broad spectrum of mutation.

We identified MECP2 mutation in 74% of the cases, the mutation detection rate is comparable with other study in which MECP2 mutations were identified in approximately 75% of RTT patients [2426] . The result suggest that MECP2 mutation is not the only cause of RTT, as there are also FOXG1 gene (locus 14q13) which causes the congenital variant of Rett syndrome and others mutations which could also lead to RTT [27]. Furthermore, we did not take into account intronic sequence change (i.e. splice site mutation) which could lead to changes in the protein structure and function. Therefore, the absent of MECP2 alone is not enough to rule out the possibility of RTT in cases where the child does not have typical symptoms or not old enough to conclude with the diagnosis of classic RTT.

The study identified 14 pathogenic mutations, including 2 missenses, 4 nonsenses, 6 frame shifts and 2 deletions. The more frequently detected mutations in our cohort (c.473 C > T; c.808 C > T, c.763 C > T and c.502C > T) are also the most common mutations reported worldwide as listed on RettBASE [18]. The mutation profile suggested that the similarity of the mutation spectrum in MECP2 is not the product of heredity, but the susceptibility of the mutation sites. We noted that most of the point mutations in our cohort are C > T in CpG sites. The CpG sites are often mutation hotspot because the cytosine in these sites is often methylated (mCpG) and 5-methylcytosine is genetically unstable [28]. In disorder like RTT, which is strictly due to de novo mutations, these CpG sites mutations became more frequent.

In our cohort, we detected a novel mutation not listed previously in any mutation databases: c.1384-1385delGT. The patient had clear clinical presentations of classic RTT. The patients had a relatively normal neurodevelopmental phase in the first 8 months, and then the child’s development regressed. At 12 months of age, she experienced a seizure and was taken to the hospital. At 3 years of age, she was unable to walk independently, and stereotypic hand movements hindered hand usage. She exhibited poor interaction to her surrounding and to other people, and show no communication ability. In silico analysis confirmed the mutation as a disease causing variant.

Before the availability of MECP2 mutation test in Vietnam, criteria for the diagnosis of Rett were solely based on clinical findings. This could lead to the under-diagnosis of Rett thus, overlooking the milder form of the disease. In order to better manage and reduce the incident of Rett we need to develop a framework to provide counseling, prenatal diagnosis for the patients and families.

Conclusions

In conclusion, the study has identified and characterized a spectrum of MECP2 mutations in sporadic case of Rett syndrome and patients with Rett like feature. Because of the clinical consequence and also the lack of data of Rett syndrome in Vietnam, future studies need to be conducted on a larger scale in different parts of the country and could provide better counseling for the patients as well as their families. The mutation spectrum of Vietnamese patients will also contribute to the global mutations database and help progress toward better understanding the etiology of the disorder and aid treatment in the near future.

Abbreviations

MECP2: 

Methyl CpG binding protein 2

MLPA: 

Multiplex Ligation-dependent Probe Amplification

PCR: 

Polymerase Chain Reaction

RTT: 

Rett Syndrome

Declarations

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. We however cannot provide personal information or data contain identification of the patients in any form.

Authors’ contributions

HLTT, LNT conceived and design the study and analysis. TDTD, CVD, HLTT contributed in data collection and carry out the experiments. HLTT, HBTP performed analysis and finalizing the results. HLTT, TDTD, LNT contributed in drafting of the manuscript. All authors have read and approved of the final version for publication.

Ethics approval and consent to participate

Written informed consent was obtained from the parents of the patients regarding the use of the samples for research purpose. The procedure was part of the patient’s care and posed no additional risk to the patients’ health. No identifiable information of the patients or their families was disclosed in our research. The study design was reviewed and approved by the Ethical board of Vinmec International Hospital. The study conformed with the Declaration of Helsinki regarding the use of human samples and identifiable information.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gene Technology - Vinmec Research Institute of Stem cell and Gene Technology, 458 Minh Khai Street, Hanoi, Hai Ba Trung district, Vietnam
(2)
Vinmec International Hospital, 458 Minh Khai Street, Hai Ba Trung District, Hanoi, Vietnam

References

  1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–8.View ArticlePubMedGoogle Scholar
  2. Hagberg B. Rett’s syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand. May 1985;74(3):405–8.View ArticlePubMedGoogle Scholar
  3. Hoffbuhr K, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology. 2001;56(11):1486–95.View ArticlePubMedGoogle Scholar
  4. Weaving LS, Ellaway CJ, Gécz J, Christodoulou J. Rett syndrome: clinical review and genetic update. J Med Genet. 2005;42(1):1–7.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Shahbazian MD, Zoghbi HY. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol. 2001;14(2):171–6.View ArticlePubMedGoogle Scholar
  6. Dunn HG, MacLeod PM. Rett syndrome: review of biological abnormalities. Can J Neurol Sci. 2001;28(1):16–29.View ArticlePubMedGoogle Scholar
  7. Lidström J, Stokland E, Hagberg B. Scoliosis in Rett syndrome. Clinical and biological aspects. Spine. 1994;19(14):1632–5.View ArticlePubMedGoogle Scholar
  8. Guideri F, Acampa M, Hayek C, Zappella M, Perri TD. Reduced heart rate variability in patients affected with Rett syndrome. A possible explanation for sudden death. Neuropediatrics. 1999;30(03):146–8.View ArticlePubMedGoogle Scholar
  9. Trabacca A, Gennaro L. A genetic cause of breathing abnormalities and severe abdominal distension. Pediatr Neurol. 2018;78:82–3.View ArticlePubMedGoogle Scholar
  10. Segawa M. Pathophysiology of Rett syndrome from the stand point of clinical characteristics. Brain and Development. Dec. 2001;23:S94–8.View ArticlePubMedGoogle Scholar
  11. Jeffrey L. Neul et al., “Rett syndrome: revised diagnostic criteria and nomenclature,” Ann Neurol, 2010 68: 6, 944–950.Google Scholar
  12. Amir RE, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol. 2000;47(5):670–9.View ArticlePubMedGoogle Scholar
  13. Ausió J. Role of MeCP2 in neurological disorders: current status and future perspectives. Epigenomics. 2018;10(1):5–8.View ArticlePubMedGoogle Scholar
  14. Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. Annu Rev Cell Dev Biol. 2011;27:631–52.View ArticlePubMedGoogle Scholar
  15. Olson CO, Zachariah RM, Ezeonwuka CD, Liyanage VRB, Rastegar M. Brain Region-Specific Expression of MeCP2 Isoforms Correlates with DNA Methylation within Mecp2 Regulatory Elements. PLoS ONE. 2014;9(3):e90645.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Qiu Z, Sylwestrak EL, Lieberman DN, Zhang Y, Liu X-Y, Ghosh A. The Rett syndrome protein MeCP2 regulates synaptic scaling. J Neurosci. 2012;32(3):989–94.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Na ES, Nelson ED, Kavalali ET, Monteggia LM. The impact of MeCP2 loss- or gain-of-function on synaptic plasticity. Neuropsychopharmacology. 2013;38(1):212–9.View ArticlePubMedGoogle Scholar
  18. Christodoulou J, Grimm A, Maher T, Bennetts B. RettBASE: the IRSA MECP2 variation database-a new mutation database in evolution. Hum Mutat. 2003;21(5):466–72.View ArticlePubMedGoogle Scholar
  19. Lam C-W, et al. Spectrum of mutations in the MECP2 gene in patients with infantile autism and Rett syndrome. J Med Genet. 2000;37(12, pp. e41–e41)Google Scholar
  20. Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet. 2003;40(2):87–95.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Adzhubei IA, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.View ArticlePubMedGoogle Scholar
  23. Hagberg B, Goutières F, Hanefeld F, Rett A, Wilson J. Rett syndrome: criteria for inclusion and exclusion. Brain and Development. 1985;7(3):372–3.View ArticlePubMedGoogle Scholar
  24. Laccone F, Huppke P, Hanefeld F, Meins M. Mutation spectrum in patients with Rett syndrome in the German population: evidence of hot spot regions. Hum Mutat. 2001;17(3):183–90.View ArticlePubMedGoogle Scholar
  25. Wan M, et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet. 1999;65(6):1520–9.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Xiang F, Buervenich S, Nicolao P, Bailey ME, Zhang Z, Anvret M. Mutation screening in Rett syndrome patients. J Med Genet. 2000;37(4):250–5.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Ariani F, et al. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet. 2008;83(1):89–93.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol. 2006;301:259–81.PubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement